Earnings summaries and quarterly performance for Upstream Bio.
Executive leadership at Upstream Bio.
Board of directors at Upstream Bio.
Research analysts covering Upstream Bio.
Recent press releases and 8-K filings for UPB.
Upstream Bio Highlights Positive Phase II Data for Verekitug and Upcoming Asthma Results
UPB
Product Launch
New Projects/Investments
- Upstream Bio (UPB) transitioned to a mid-stage clinical development company in 2025, marked by the release of positive Phase II placebo-controlled data for verekitug in chronic rhinosinusitis with nasal polyps (CRS with NP).
- The Phase II CRS with NP data for verekitug demonstrated strong efficacy with every 12-week dosing, positioning it as potentially best-in-class.
- Verekitug is a monoclonal antibody that uniquely targets the TSLP receptor, offering the potential for extended dosing intervals (up to 24 weeks after the last dose) and enhanced potency compared to ligand-targeting therapies.
- The company expects to release severe asthma data in the first quarter of 2026, aiming for approximately a 50% reduction in annualized asthma exacerbation rate with Q12 week dosing.
- Upstream Bio is also progressing a Phase II COPD trial, which began dosing patients over the summer, with the goal of demonstrating efficacy across a broad patient population.
Dec 4, 2025, 3:25 PM
Upstream Bio discusses Virectib clinical trial progress and future plans
UPB
New Projects/Investments
- Upstream Bio's biggest accomplishment in 2025 was transitioning to a mid-stage development company, highlighted by positive Phase 2 placebo-controlled data for Virectib in chronic rhinosinusitis with nasal polyps (CRS with NP).
- Virectib is a monoclonal antibody targeting the TSLP receptor, distinguishing it from competitors like Tezepelamab, and allows for extended every 12-week dosing.
- The Phase 2 Vibrant study in CRS with NP showed a 1.8-point reduction in the endoscopic nasal polyp score, significant reductions in nasal congestion, and improved sinusitis, all delivered at Q12 week dosing.
- Upstream Bio anticipates releasing severe asthma data (Valiant study) in Q1 2026, aiming for approximately a 50% reduction in annualized asthma exacerbation rate with Q12 week dosing.
- The company plans to wait for the asthma data before initiating Phase 3 trials for both CRS with NP and severe asthma, with the goal of potentially launching in both indications around the same time. A Phase 2 COPD trial is also underway, with data expected further out.
Dec 4, 2025, 3:25 PM
Upstream Bio Discusses Virectib Clinical Development and Upcoming Asthma Data
UPB
New Projects/Investments
Guidance Update
- Upstream Bio has transitioned to a mid-stage clinical development company, reporting positive Phase 2 placebo-controlled data for Virectib in chronic rhinosinusitis with nasal polyps (CRS with NP), demonstrating strong efficacy with every 12-week dosing.
- The company expects to release data for Virectib in severe asthma (Valiant study) in the first quarter of 2026, with the positive CRS data increasing confidence for this upcoming readout.
- Virectib differentiates itself by targeting the TSLP receptor, which contributes to its high potency and potential for extended dosing intervals (Q12 week, with potential for Q24 week).
- Following the asthma data, Upstream Bio intends to initiate Phase 3 development for both CRS with NP and severe asthma, aiming for a potential simultaneous launch.
Dec 4, 2025, 3:25 PM
Upstream Bio Confirms Q1 2026 Verekitug Asthma Data Readout and Outlines Phase 3 Strategy
UPB
Guidance Update
New Projects/Investments
- Upstream Bio anticipates Verekitug asthma data readout in Q1 2026, confirming previous guidance, following enrollment completion on June 9, 2025, for its 24-week study.
- The company aims for a 50% reduction in exacerbations on a placebo-adjusted basis for Verekitug, with potential for a highly differentiated profile due to its extended dosing intervals (quarterly or every six months) and several hundred-fold greater potency compared to Tezepelamab.
- Upstream Bio plans to leverage data from both severe asthma and chronic rhinosinusitis with nasal polyps (CRS with NP) trials for robust dose selection for Phase 3, with the ambition to prosecute both programs approximately simultaneously, ideally with a single dose regimen for both diseases.
Dec 2, 2025, 9:30 PM
Upstream Bio Provides Update on VALIANT Asthma Data and Phase 3 Development Plans
UPB
Guidance Update
New Projects/Investments
- Upstream Bio (UPB) anticipates the release of VALIANT asthma data in Q1 2026, following the completion of enrollment on June 9th and a 24-week study period.
- The company is targeting a 50% reduction in exacerbations for its verekitug treatment in severe asthma, aiming for a highly differentiated profile with quarterly (Q12 weeks) or every six months (Q24 weeks) dosing intervals.
- Verekitug demonstrates significantly higher potency than tezepelamab, which is expected to support extended dosing and broad patient eligibility, positioning it competitively against existing biologics.
- Upstream Bio plans to leverage data from both severe asthma and chronic rhinosinusitis with nasal polyps trials to select a single dose regimen for Phase 3, with the ambition to simultaneously advance both programs.
Dec 2, 2025, 9:30 PM
Upstream Bio Provides Update on Verekitug Asthma Program and Market Strategy
UPB
Guidance Update
New Projects/Investments
- Upstream Bio (UPB) anticipates the Verekitug asthma data readout in Q1 2026, with enrollment completion on June 9th and a 24-week study period aligning with a February/March timeline.
- The company expects a 50% reduction in exacerbations on a placebo-adjusted basis for Verekitug, which would represent a highly differentiated profile if achieved at quarterly or every six months dosing intervals.
- Verekitug has demonstrated several hundred-fold greater potency than Tezepelamab in the clinic, enabling potential extended dosing intervals of every 12 weeks or every 24 weeks.
- UPB plans to leverage data from both severe asthma and chronic rhinosinusitis with nasal polyps (CRS with NP) trials for robust Phase 3 dose selection, with the ambition to initiate both programs approximately simultaneously.
- The company sees significant market opportunity in asthma, where biologics currently have less than 10% penetration of eligible patients, believing a differentiated agent like Verekitug could drive further market growth.
Dec 2, 2025, 9:30 PM
Upstream Bio Provides Update on Verekitug Clinical Development
UPB
New Projects/Investments
- Upstream Bio reported positive Phase 2 data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), demonstrating efficacy that meets or exceeds available biologics at Q12 week dosing and a 76% reduction in systemic steroid use or surgery.
- Phase 2 data for severe asthma with verekitug, testing Q12 and Q24 week dosing, is expected in Q1 (next year). The trial is powered to detect a 50% or greater reduction in asthma exacerbations.
- The company plans to use data from both CRSwNP and severe asthma studies to inform Phase 3 dose selection, aiming for a single dose across both indications.
- Upstream Bio highlights verekitug's mechanistic differentiation as the only antibody hitting the TSLP receptor, which contributes to its potency and extended dosing potential compared to competitors targeting the ligand.
Nov 12, 2025, 3:30 PM
Upstream Bio Reports Positive Phase 2 CRS with NP Data, Anticipates Severe Asthma Results in Q1 2026
UPB
New Projects/Investments
Product Launch
Guidance Update
- Upstream Bio recently reported positive Phase 2 data for Viracetag in Chronic Rhinosinusitis with Nasal Polyps (CRS with NP) in September. The trial met its primary endpoint of reducing the endoscopic nasal polyp score by 1.8 points and all secondary endpoints, demonstrating efficacy comparable to or exceeding other biologics with four times per year dosing.
- The company anticipates reading out data from its Phase 2 Valiant trial in severe asthma in Q1 2026. Patient enrollment has also begun for a Phase 2 trial in Chronic Obstructive Pulmonary Disease (COPD).
- Upstream Bio is well-funded, with capital projected to support operations through 2027.
- Viracetag is a unique monoclonal antibody targeting the TSLP receptor, which the company believes offers potential differentiation in efficacy and an extended dosing interval (Q12 or Q24 weeks) compared to competitors targeting the ligand.
- The market for biologics in these indications (CRS with NP, severe asthma, COPD) is estimated to exceed $35 billion by the mid-2030s.
Nov 11, 2025, 2:20 PM
Upstream Bio Provides Update on Virecotug Development and Market Opportunity
UPB
New Projects/Investments
Guidance Update
- Upstream Bio is a clinical-stage company developing virecotug, a monoclonal antibody targeting the TSLP receptor for severe respiratory diseases, which offers potential for differentiated efficacy and extended dosing intervals due to its potency.
- The company recently reported positive Phase 2 data for virecotug in chronic rhinosinusitis with nasal polyps (CRS with NP) in September, meeting its primary endpoint and all secondary endpoints, including a 76% reduction in the need for surgery or systemic steroids.
- Upstream Bio anticipates reading out data from its Phase 2 trial (VALIANT) in severe asthma in the first quarter of next year and has initiated patient enrollment for its Phase 2 trial in chronic obstructive pulmonary disease (COPD).
- The market for biologics in these indications is estimated to reach $35 billion by the mid-2030s, and Upstream Bio is well-funded to support operations through 2027.
Nov 11, 2025, 2:20 PM
Upstream Bio Reports Third Quarter 2025 Financial Results and Clinical Trial Progress
UPB
Earnings
Guidance Update
New Projects/Investments
- Upstream Bio reported a net loss of $33.7 million for the third quarter ended September 30, 2025, an increase from a net loss of $16.0 million for the same period in 2024, largely due to increased research and development expenses.
- Research and development expenses for the quarter ended September 30, 2025, were $33.0 million, up from $15.4 million in the prior year's period, primarily driven by its verekitug programs.
- As of September 30, 2025, the company had $372.4 million in cash, cash equivalents, and short-term investments, which is expected to fund planned operations through 2027.
- The company announced positive top-line results in September 2025 from its VIBRANT Phase 2 trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), demonstrating statistically significant and clinically meaningful effects on primary and key secondary endpoints.
- Upstream Bio is on track to report top-line results from its VALIANT Phase 2 trial in severe asthma in the first quarter of 2026, and enrollment is ongoing for the VENTURE Phase 2 trial in COPD.
Nov 5, 2025, 12:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more